FY2025 EPS Estimates for Exagen Lowered by Cantor Fitzgerald

Exagen Inc. (NASDAQ:XGN) – Stock analysts at Cantor Fitzgerald reduced their FY2025 earnings estimates for Exagen in a research report issued on Wednesday, March 12th. Cantor Fitzgerald analyst R. Osborn now forecasts that the company will post earnings per share of ($0.59) for the year, down from their previous forecast of ($0.41). Cantor Fitzgerald has a “Overweight” rating and a $8.00 price objective on the stock. The consensus estimate for Exagen’s current full-year earnings is ($0.88) per share.

XGN has been the subject of a number of other research reports. William Blair reaffirmed an “outperform” rating on shares of Exagen in a research note on Wednesday. Canaccord Genuity Group raised their price target on shares of Exagen from $5.00 to $7.00 and gave the company a “buy” rating in a research report on Friday, January 3rd.

Exagen Price Performance

Shares of NASDAQ XGN opened at $3.56 on Friday. Exagen has a fifty-two week low of $1.30 and a fifty-two week high of $6.22. The company has a 50 day simple moving average of $3.78 and a two-hundred day simple moving average of $3.57. The company has a market capitalization of $62.79 million, a price-to-earnings ratio of -3.79 and a beta of 1.40. The company has a debt-to-equity ratio of 1.54, a quick ratio of 4.05 and a current ratio of 4.05.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of XGN. Toronto Dominion Bank purchased a new position in shares of Exagen during the 4th quarter valued at $3,655,000. Driehaus Capital Management LLC purchased a new stake in Exagen in the 4th quarter worth $1,716,000. Stonepine Capital Management LLC lifted its stake in Exagen by 49.0% in the 3rd quarter. Stonepine Capital Management LLC now owns 534,398 shares of the company’s stock worth $1,651,000 after purchasing an additional 175,701 shares in the last quarter. Marshall Wace LLP bought a new stake in shares of Exagen in the 4th quarter worth about $66,000. Finally, Kennedy Capital Management LLC increased its holdings in shares of Exagen by 8.8% in the 4th quarter. Kennedy Capital Management LLC now owns 184,473 shares of the company’s stock worth $756,000 after buying an additional 14,920 shares during the last quarter. Hedge funds and other institutional investors own 75.25% of the company’s stock.

Exagen Company Profile

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).